Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Drug

BioNTech’s mRNA Cancer Immunotherapy BNT111 Achieves Primary Endpoint in Phase II Trial

Fineline Cube Jul 31, 2024

Germany-based BioNTech SE (NASDAQ: BNTX) has announced that its mRNA cancer immunotherapy BNT111, in combination...

Company

Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak

Fineline Cube Jul 31, 2024

Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...

Company

Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises

Fineline Cube Jul 31, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...

Company Drug

FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab

Fineline Cube Jul 31, 2024

US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...

Company Deals

National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China

Fineline Cube Jul 31, 2024

The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has...

Policy / Regulatory

China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System

Fineline Cube Jul 31, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have...

Company Deals

Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline

Fineline Cube Jul 31, 2024

Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful...

Policy / Regulatory

China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs

Fineline Cube Jul 31, 2024

In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Receives European Commission Approval

Fineline Cube Jul 31, 2024

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that its biosimilar version of Roche’s Avastin, Avzivi...

Company Drug

Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals

Fineline Cube Jul 31, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has...

Company Medical Device

MicroPort Scientific’s Fully Biodegradable Cardiac Stent Earns NMPA Nod

Fineline Cube Jul 31, 2024

Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company Deals

Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility

Fineline Cube Jul 31, 2024

Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in...

Company

Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization

Fineline Cube Jul 31, 2024

Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...

Company Drug

Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA

Fineline Cube Jul 31, 2024

Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...

Policy / Regulatory

China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies

Fineline Cube Jul 31, 2024

The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...

Company

WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges

Fineline Cube Jul 30, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...

Company Deals

Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business

Fineline Cube Jul 30, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...

Company

Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand

Fineline Cube Jul 30, 2024

Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...

Company Deals

GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines

Fineline Cube Jul 30, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...

Company Drug

Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment

Fineline Cube Jul 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...

Posts pagination

1 … 315 316 317 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.